InVivo Therapeutics Holdings Corp. said that Jeffrey Hatfield will resign from the board and its audit and compensation committees, effective Dec. 31.

Hatfield's resignation is not due to any conflict or disagreement with the company or its board, InVivo Therapeutics said in a Dec. 10 regulatory document.

InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company that develops scaffolding devices for spinal cord injuries.